Exhibit 1

 

JOINT FILING AGREEMENT

 

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them as a statement on Schedule 13G (including amendments thereto) with respect to the common shares of Hemab Therapeutics Holdings, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to this agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.

 

In evidence whereof, the undersigned have caused this agreement to be executed on their behalf on August 5, 2026.

 

Sofinnova Crossover II SLP   Sofinnova Partners SAS, a French corporation  
         
By:   /s/ Antonie Papiernik   By:   /s/ Antonie Papiernik
         
Name: Antonie Papiernik   Name: Antonie Papiernik
         
Title: Managing Partner   Title: Managing Partner

 

 

By:   /s/ Antonie Papiernik   By:   /s/ Cédric Moreau
         
Name: Antonie Papiernik   Name: Cédric Moreau

 

 

By:   /s/ Kinam Hong   By:   /s/ Joseph Anderson
         
Name: Kinam Hong   Name: Joseph Anderson

 

 

By:   /s/ David Evans      
         
Name: David Evans